These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 7945742)

  • 1. Does a placebo run-in or a placebo treatment cell affect the efficacy of antidepressant medications?
    Trivedi MH; Rush H
    Neuropsychopharmacology; 1994 Aug; 11(1):33-43. PubMed ID: 7945742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does the presence of an open-label antidepressant treatment period influence study outcome in clinical trials examining augmentation/combination strategies in treatment partial responders/nonresponders with major depressive disorder?
    Iovieno N; Papakostas GI
    J Clin Psychiatry; 2012 May; 73(5):676-83. PubMed ID: 22569112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy in long-term treatment of depression.
    Montgomery SA
    J Clin Psychiatry; 1996; 57 Suppl 2():24-30. PubMed ID: 8626360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psychiatry should not become hostage to placebo: an alternative interpretation of antidepressant-placebo differences in the treatment response in depression.
    Rihmer Z; Dome P; Baldwin DS; Gonda X
    Eur Neuropsychopharmacol; 2012 Nov; 22(11):782-6. PubMed ID: 22497852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Placebo response and antidepressant clinical trial outcome.
    Khan A; Detke M; Khan SR; Mallinckrodt C
    J Nerv Ment Dis; 2003 Apr; 191(4):211-8. PubMed ID: 12695731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Considering the case for an antidepressant drug trial involving temporary deception: a qualitative enquiry of potential participants.
    Dowrick CF; Hughes JG; Hiscock JJ; Wigglesworth M; Walley TJ
    BMC Health Serv Res; 2007 Apr; 7():64. PubMed ID: 17470280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analyses.
    Sinyor M; Levitt AJ; Cheung AH; Schaffer A; Kiss A; Dowlati Y; Lanctôt KL
    J Clin Psychiatry; 2010 Mar; 71(3):270-9. PubMed ID: 20122371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
    Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
    J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation between different levels of placebo response rate and clinical trial outcome in major depressive disorder: a meta-analysis.
    Iovieno N; Papakostas GI
    J Clin Psychiatry; 2012 Oct; 73(10):1300-6. PubMed ID: 23140647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors that influence the outcome of placebo-controlled antidepressant clinical trials.
    Niklson IA; Reimitz PE; Sennef C
    Psychopharmacol Bull; 1997; 33(1):41-51. PubMed ID: 9133750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nefazodone: aspects of efficacy.
    Rickels K; Robinson DS; Schweizer E; Marcus RN; Roberts DL
    J Clin Psychiatry; 1995; 56 Suppl 6():43-6. PubMed ID: 7649973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Placebo-controlled antidepressant drug trials. Considering the ethical implications].
    Deisenhammer EA; Hinterhuber H
    Fortschr Neurol Psychiatr; 2003 May; 71(5):243-8. PubMed ID: 12740755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complementary and alternative medicine for major depressive disorder: a meta-analysis of patient characteristics, placebo-response rates, and treatment outcomes relative to standard antidepressants.
    Freeman MP; Mischoulon D; Tedeschini E; Goodness T; Cohen LS; Fava M; Papakostas GI
    J Clin Psychiatry; 2010 Jun; 71(6):682-8. PubMed ID: 20573327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A reevaluation of the exclusion criteria used in antidepressant efficacy trials.
    Posternak MA; Zimmerman M; Keitner GI; Miller IW
    Am J Psychiatry; 2002 Feb; 159(2):191-200. PubMed ID: 11823258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The persistence of the placebo response in antidepressant clinical trials.
    Khan A; Redding N; Brown WA
    J Psychiatr Res; 2008 Aug; 42(10):791-6. PubMed ID: 18036616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severity of depressive symptoms and response to antidepressants and placebo in antidepressant trials.
    Khan A; Brodhead AE; Kolts RL; Brown WA
    J Psychiatr Res; 2005 Mar; 39(2):145-50. PubMed ID: 15589562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-placebo difference: in antidepressant drug trials could be 50% greater than previously believed.
    Rihmer Z
    Neuropsychopharmacol Hung; 2007 Mar; 9(1):35-7. PubMed ID: 17879563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meta-analysis of the placebo response in antidepressant trials.
    Rief W; Nestoriuc Y; Weiss S; Welzel E; Barsky AJ; Hofmann SG
    J Affect Disord; 2009 Nov; 118(1-3):1-8. PubMed ID: 19246102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is drug-placebo difference in short-term antidepressant drug trials on unipolar major depression much greater than previously believed?
    Rihmer Z; Gonda X
    J Affect Disord; 2008 Jun; 108(3):195-8. PubMed ID: 18280581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design makes a difference: a meta-analysis of antidepressant response rates in placebo-controlled versus comparator trials in late-life depression.
    Sneed JR; Rutherford BR; Rindskopf D; Lane DT; Sackeim HA; Roose SP
    Am J Geriatr Psychiatry; 2008 Jan; 16(1):65-73. PubMed ID: 17998306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.